E
Enliven Therapeutics, Inc.
ELVN · NASDAQ · Healthcare · 4.2B
Price · close
$59.82
+1.53% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
7.4×
Enterprise value / EBITDAEV/EBITDA
-31.8×
Free cash flow yieldFCF yield
-2.1%
Return on equityROE
-22.6%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
1.0×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.